Vimarsana
Biggest News Aggregation in the World

Page 17 - Eric Ribner News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eric Ribner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eric Ribner Today - Breaking & Trending Today

Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility - Vimarsana News

Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy - Vimarsana News

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

/PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious...

Enlivex: After Review of Phase II Data, Israeli Ministry of - Vimarsana News

Enlivex: After Review of Phase II Data, Israeli Ministry of

Nes Ziona, Israel, Aug. 15, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients - Press Release - Vimarsana News

Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients - Press Release

Nes Ziona, Israel, Aug. 15, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company")), a clinical-stage macrophage reprogrammin

Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank - Vimarsana News

Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank

Share: NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered into a new $25 million credit financing facility with Silicon Valley Bank (SVB). "This non-dilutive credit facility provides us with a significant amount of financial and operating flexibility at terms that we believe are favorable to the company," stated Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. "These fu...